X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6248) 6248
Publication (424) 424
Book Review (53) 53
Magazine Article (13) 13
Dissertation (6) 6
Book Chapter (5) 5
Conference Proceeding (3) 3
Paper (3) 3
Data Set (2) 2
Newspaper Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atorvastatin (4243) 4243
humans (4133) 4133
male (3469) 3469
index medicus (3428) 3428
female (2746) 2746
statins (2489) 2489
middle aged (2294) 2294
atorvastatin calcium (2252) 2252
aged (1746) 1746
pharmacology & pharmacy (1487) 1487
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1466) 1466
cholesterol (1428) 1428
simvastatin (1405) 1405
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (1390) 1390
animals (1363) 1363
pyrroles - administration & dosage (1338) 1338
heptanoic acids - administration & dosage (1336) 1336
cardiac & cardiovascular systems (1297) 1297
treatment outcome (1218) 1218
adult (1164) 1164
pyrroles - therapeutic use (1095) 1095
heptanoic acids - therapeutic use (1093) 1093
cholesterol, ldl - blood (866) 866
risk factors (804) 804
atherosclerosis (779) 779
pravastatin (778) 778
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (769) 769
dose-response relationship, drug (763) 763
heptanoic acids - pharmacology (754) 754
pyrroles - pharmacology (754) 754
rats (724) 724
lipids (699) 699
prevention (696) 696
therapy (680) 680
antilipemic agents (677) 677
anticholesteremic agents - administration & dosage (661) 661
risk (650) 650
hypercholesterolemia (636) 636
analysis (635) 635
anticholesteremic agents - therapeutic use (626) 626
hypercholesterolemia - drug therapy (625) 625
drug therapy, combination (607) 607
drug therapy (604) 604
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (599) 599
rosuvastatin (597) 597
care and treatment (585) 585
statin (577) 577
peripheral vascular disease (575) 575
inflammation (562) 562
research (560) 560
medicine, general & internal (534) 534
disease (523) 523
time factors (523) 523
double-blind method (520) 520
dosage and administration (517) 517
cardiovascular (516) 516
coronary-heart-disease (504) 504
cardiovascular diseases (496) 496
abridged index medicus (476) 476
cardiovascular disease (472) 472
prospective studies (466) 466
efficacy (451) 451
mortality (444) 444
mice (440) 440
c-reactive protein (430) 430
statin therapy (430) 430
safety (427) 427
cholesterol - blood (426) 426
oxidative stress (397) 397
cardiovascular-disease (394) 394
follow-up studies (394) 394
myocardial-infarction (393) 393
cardiovascular agents (380) 380
pyrroles - adverse effects (374) 374
ezetimibe (373) 373
heptanoic acids - adverse effects (372) 372
rosuvastatin calcium (371) 371
simvastatin - administration & dosage (371) 371
low density lipoproteins (370) 370
aged, 80 and over (369) 369
drug interactions (369) 369
expression (366) 366
health aspects (358) 358
lipids - blood (358) 358
coronary heart disease (357) 357
triglycerides - blood (356) 356
simvastatin - therapeutic use (354) 354
cardiology (349) 349
diabetes (346) 346
drug administration schedule (338) 338
medicine & public health (338) 338
metaanalysis (334) 334
pharmacokinetics (329) 329
cardiovascular diseases - prevention & control (327) 327
medicine, research & experimental (321) 321
disease models, animal (316) 316
cholesterol, hdl - blood (312) 312
internal medicine (310) 310
studies (310) 310
hypercholesterolemia - blood (307) 307
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6038) 6038
Russian (55) 55
German (46) 46
Spanish (33) 33
Chinese (24) 24
French (22) 22
Japanese (10) 10
Hungarian (9) 9
Italian (6) 6
Polish (5) 5
Ukrainian (5) 5
Swedish (4) 4
Czech (3) 3
Danish (2) 2
Lithuanian (2) 2
Norwegian (2) 2
Persian (2) 2
Portuguese (2) 2
Croatian (1) 1
Dutch (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 9, pp. 1140 - 1146
Three-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are first-line treatments for hypercholesterolemia. Although exceedingly well... 
CLARITHROMYCIN | INDUCED RHABDOMYOLYSIS | LOVASTATIN | CARDIAC & CARDIOVASCULAR SYSTEMS | CONCOMITANT USE | ERYTHROMYCIN | FATAL RHABDOMYOLYSIS | ITRACONAZOLE | ROSUVASTATIN | DRUG-INTERACTION | CYCLOSPORINE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 Enzyme System - administration & dosage | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Mibefradil - pharmacokinetics | Male | Protein Synthesis Inhibitors - administration & dosage | Verapamil - administration & dosage | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Antiprotozoal Agents - pharmacokinetics | Drug Interactions | Itraconazole - pharmacokinetics | Pyrroles - administration & dosage | Clarithromycin - pharmacokinetics | Mibefradil - administration & dosage | Clarithromycin - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Itraconazole - administration & dosage | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Verapamil - pharmacokinetics | Biomarkers - blood | Simvastatin - pharmacokinetics | Protein Synthesis Inhibitors - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Antiprotozoal Agents - administration & dosage | Calcium Channel Blockers - administration & dosage | Creatine Kinase - drug effects | Calcium Channel Blockers - pharmacokinetics | Pravastatin - pharmacokinetics
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2011, Volume 103, Issue 11, pp. 885 - 892
Journal Article
Journal Article
European Journal of Preventive Cardiology, ISSN 2047-4873, 12/2015, Volume 22, Issue 12, pp. 1609 - 1617
Journal Article
Journal Article
American journal of physiology. Cell physiology, ISSN 0363-6143, 09/2019, Volume 317, Issue 5, pp. C894 - C899
Statins are a cholesterol-lowering drug class that significantly reduce cardiovascular disease risk. Despite their safety and effectiveness, musculoskeletal... 
Oxidative stress | Reactive oxygen species | Pain perception | Myotubes | Acetylcysteine | Amino acids | Myalgia | Skeletal muscle | Cholesterol | Antioxidants | Musculoskeletal system | Hypotheses | Side effects | Mitochondria | Fibroblasts | Atorvastatin | Sulfasalazine | Cardiovascular diseases | Statins | Glutathione
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 11/2017, Volume 56, Issue 11, pp. 1415 - 1427
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2013, Volume 69, Issue 3, pp. 477 - 487
Interactions between ticagrelor and atorvastatin or simvastatin were investigated in two-way crossover studies.Both studies were open-label for statin; the... 
Co-administration | AZD6140 | Biomedicine | Simvastatin | Atorvastatin | Pharmacology/Toxicology | Ticagrelor | Pharmacokinetics | COA REDUCTASE INHIBITORS | SLCO1B1 POLYMORPHISM | ACUTE CORONARY SYNDROMES | CLINICAL PHARMACOKINETICS | STATINS | RECEPTOR ANTAGONIST | SERUM CONCENTRATIONS | TASK-FORCE | PHARMACOLOGY & PHARMACY | P2Y RECEPTOR | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Adenosine - pharmacokinetics | Purinergic P2Y Receptor Antagonists - administration & dosage | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Half-Life | Male | Metabolic Clearance Rate | Heptanoic Acids - adverse effects | Simvastatin - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Pyrroles - administration & dosage | Adenosine - adverse effects | Biotransformation | Platelet Aggregation Inhibitors - administration & dosage | Heptanoic Acids - administration & dosage | Pyrroles - adverse effects | Adult | Female | Platelet Aggregation Inhibitors - pharmacokinetics | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Drug Administration Schedule | Simvastatin - administration & dosage | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Linear Models | Pyrroles - blood | Simvastatin - pharmacokinetics | Adenosine - administration & dosage | Cross-Over Studies | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adenosine - analogs & derivatives | Least-Squares Analysis | Heptanoic Acids - blood | Dosage and administration | Metabolites | Drug interactions | Antilipemic agents | Drug therapy | Pharmacology | Kinetics
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 10/2015, Volume 104, Issue 10, pp. 3490 - 3500
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2014, Volume 73, Issue 1, pp. 124 - 131
Objectives To evaluate the efficacy and safety of atorvastatin versus placebo in modifying lipids in patients with rheumatoid arthritis (RA) receiving the oral... 
JAK INHIBITOR | MODIFYING ANTIRHEUMATIC DRUGS | Rheumatoid Arthritis | INADEQUATE RESPONSE | METHOTREXATE | Lipids | RISK | RHEUMATOLOGY | OF-THE-ART | CP-690,550 | PATHOGENESIS | Treatment | CARDIOVASCULAR-DISEASE | PLACEBO-CONTROLLED TRIAL | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Follow-Up Studies | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Heptanoic Acids - adverse effects | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Cardiovascular Diseases - complications | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Lipids - blood | Heptanoic Acids - administration & dosage | Placebos | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Atorvastatin Calcium | Protein Kinase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Piperidines - adverse effects | Pyrimidines - adverse effects | Dosage and administration | Research | Tofacitinib | Drug therapy | Rheumatoid arthritis | Studies | Disease | Cytokines | Mortality | Neutrophils | Family medical history | Low density lipoprotein | Drug dosages | Cholesterol
Journal Article